GLP-1 Muscle Loss Meets Myostatin Blocking Therapy

A phase 2 trial suggests apitegromab may help preserve lean mass during tirzepatide weight loss, but larger studies are needed before this becomes routine obesity care.

A new phase 2 clinical trial found that adding apitegromab, an investigational antibody that blocks myostatin activation, helped adults taking tirzepatide lose less lean body mass while achieving similar total weight loss.

The finding matters because patients using GLP-1 and GLP-1/GIP medications often ask whether rapid weight loss means losing too much muscle. This study suggests muscle-preserving add-on therapy may become part of obesity medicine, but it is not ready to replace protein intake, resistance training, or careful clinical monitoring.

Study Details

Tirzepatide has changed obesity treatment by producing substantial weight loss in many patients. But weight loss is not only fat loss. Lean body mass, which includes skeletal muscle, bone, organs, connective tissue, and body water, can also decline during treatment.

That concern has become more visible as GLP-1 based therapies move from specialist obesity clinics into primary care, endocrinology, cardiology, and metabolic medicine. For patients, the fear is practical: will weight loss make me weaker, less functional, or more likely to regain fat later? For clinicians, the question is whether body composition should become a more formal part of obesity treatment planning.

Apitegromab targets myostatin, a protein that normally limits skeletal muscle growth. By inhibiting myostatin activation, the drug is designed to preserve or increase muscle-related tissue. In this study, researchers tested whether that biology could improve the quality of weight loss during tirzepatide treatment.

Methodology

The EMBRAZE trial was a randomized, double-blind, placebo-controlled phase 2 study conducted in adults with overweight or obesity. A total of 102 participants were assigned to receive tirzepatide plus apitegromab or tirzepatide plus placebo for 24 weeks.

Both groups received tirzepatide. The difference was whether participants also received apitegromab or placebo by intravenous infusion every 4 weeks. Tirzepatide was started at 2.5 mg weekly and increased according to the usual dose-escalation schedule as tolerated.

Researchers used DEXA scans to measure body composition before and after treatment. The primary question was whether apitegromab reduced the amount of lean body mass lost during tirzepatide-induced weight loss. The study also tracked body weight, fat mass, adverse events, exploratory physical function measures, and follow-up body composition after treatment ended.

Key Findings

• Total weight loss was similar in both groups. Participants receiving tirzepatide plus apitegromab lost about 11.2 kg, while those receiving tirzepatide plus placebo lost about 12.5 kg.

• Lean body mass accounted for a smaller share of total weight loss with apitegromab. In the apitegromab group, lean mass represented 14.6% of total weight loss, compared with 30.2% in the placebo group.

• Participants receiving apitegromab lost 1.9 kg less lean body mass than those receiving placebo at 24 weeks. This represented a 54.9% relative preservation of lean mass compared with placebo.

• Fat mass made up a larger proportion of weight loss in the apitegromab group, suggesting a more favorable body composition profile during treatment.

• The lean mass difference remained partly visible 8 weeks after treatment stopped, although the effect was smaller.

• Adverse events were broadly similar between groups. Nausea, fatigue, and headache were reported more often with apitegromab, but most events were mild and transient.

• The trial did not show clear improvement in physical function or cardiometabolic outcomes over 24 weeks. This is important because preserving lean mass on a scan is not the same as proving stronger muscles, better mobility, or better long-term health.

Implications for Practice

For patients, the message is encouraging but cautious. This study supports the idea that future obesity treatment may focus not only on how many pounds are lost, but also on what kind of tissue is lost. That is a better frame for long-term health than scale weight alone.

But apitegromab is not a do-it-yourself muscle-preservation strategy. It is an investigational antibody in this obesity context, given by infusion in a clinical trial setting. Patients taking tirzepatide, semaglutide, or other GLP-1 based treatments should still prioritize resistance training, adequate dietary protein, sleep, and gradual dose management with their clinician.

For healthcare providers, this trial is a signal that body composition may become a more important endpoint in obesity medicine. DEXA-measured lean mass preservation is biologically plausible and clinically interesting, especially for older adults, frail patients, patients with sarcopenic obesity, and those who struggle to exercise during weight loss.

However, the limitations matter. The study was small, lasted only 24 weeks, included mostly female participants, and excluded patients with diabetes and significant cardiometabolic disease. That means the results may not apply to many real-world patients who receive GLP-1 therapy, including those with type 2 diabetes, cardiovascular disease, chronic kidney disease, or complex obesity-related complications.

The practical takeaway for clinicians is not that every GLP-1 patient needs a myostatin antibody. The better takeaway is that GLP-1 care should become more deliberate: assess strength, function, protein intake, resistance exercise, frailty risk, and weight-regain risk. If larger trials confirm these findings, muscle-preserving therapies may eventually become an add-on option for selected patients.

For now, apitegromab is best viewed as an early proof-of-concept: it may improve the composition of weight loss during tirzepatide therapy, but it has not yet proven that patients feel stronger, function better, avoid frailty, or maintain better metabolic health long term.